Cookie Preferences
By clicking “Accept All”, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage and assist in our marketing efforts as outlined in our cookie policy.
Strictly Necessary (Always Active)
Cookies required to enable basic website functionality.
Cookies helping us understand how this website performs, how visitors interact with the site, and whether there may be technical issues.
Cookies used to deliver advertising that is more relevant to you and your interests.
Cookies allowing the website to remember choices you make (such as your user name, language, or the region you are in).

Ventures

Invest in breakthrough healthtech solutions that transform patients' lives.

00:00
/
00:00
00:00
/
00:00
Invest in transformative health innovations
Invest in transformative health innovations

We vet over 1500 innovations yearly and identify, build, and invest in 20 to 25 ventures that address crucial, unmet needs in the healthcare sector. Our ventures lead in areas such as personalized medicine, AI diagnostics, and medical devices, all of which show substantial potential for growth, return, and impact.

00:00
/
00:00
00:00
/
00:00
Invest alongside NLC
Invest alongside NLC

As an investor in an NLC venture, you always invest alongside NLC. Our team of 80+ experts offers comprehensive support to our ventures, including regulatory guidance, product development assistance, and clinical trial setup. This extensive, tailored support system de-risks your investment and enhances the likelihood of venture success. Single-company investments start at €25K.

00:00
/
00:00
00:00
/
00:00
Invest with impact
Invest with impact

By investing in one of our ventures, you help bring transformative health solutions to patients in need, directly impacting their lives. NLC is a certified B Corp and supports UN Sustainable Development Goals 3, 9, and 17, our funds are SDFR-9 compliant, which means we adhere to the strictest impact regulations. Investing in NLC ventures can be your pathway to high-impact capital deployment.

Receive the latest investment opportunities that match your interests, directly in your inbox. Stay informed and never miss out.

a highlight from our portfolio

Angiogenesis Analytics

Angiogenesis Analytics

Angiogenesis Analytics is transforming prostate cancer diagnosis by integrating artificial intelligence with advanced ultrasound technology. Our mission is to make the detection of prostate cancer quicker, more affordable, and significantly less invasive than traditional methods. By pioneering the innovative PCAVision technology, we are setting new standards in healthcare.
Visit website
Download documents
PEP Health

PEP Health

PEP Health is revolutionizing how healthcare providers understand and improve patient experiences by leveraging machine-learning technology to give healthcare organizations, regulators, and insurers the real-time, actionable insights they need to have a direct and dramatic impact on patient experiences.
Visit website
Download documents
Amotio
Easier joint implant revision surgery through 3D technology

Amotio addresses the challenge of revision surgeries for hip, knee, and shoulder implants with their innovative approach. Collaborating with expert revision surgeons and guided by NLC, they offer a patented solution for improved implant revision surgery. By developing unique bone cement removal devices and integrating advanced patient-specific 3D surgical planning and printing technology, Amotio aims to set a new standard for excellence in these surgeries. Their goal is to reduce complexity, trauma, and recovery time while cutting costs for healthcare providers.

Active
🇳🇱 Netherlands
Amotio
Sigilla Medical
Sigilla Medical has developed an implant-free device and procedure that safely closes PFOs with minimal complications, improving patient outcomes.

Sigilla Medical is developing an innovative, implant-free radiofrequency device designed to close PFOs (patent foramen ovale) in stroke-risk patients. PFOs are associated with cryptogenic stroke and migraine, and current treatment involves placing a large metal device that spans the septum of the heart in an otherwise young and healthy patient. Sigilla’s device offers a safer, more efficient alternative by using controlled radiofrequency to seal the PFO without the need for implants. This less-invasive approach reduces procedural risk and adverse cardiac events while leaving options open for future minimally invasive procedures.

Active
🇮🇪 Ireland
Sigilla Medical
Persuasive
Early and easy detection of ischemic heart disease

Persuasive addresses the challenge of identifying Stable Angina patients early on, crucial for preventing heart attacks. Currently, without a diagnostic test in general practitioner settings, many referrals to hospitals prove unnecessary. The solution is a simple blood test, leveraging an extracellular vesicle protein signature to distinguish SA patients from those with non-cardiac chest pain. This innovative approach promises to streamline patient management, saving lives and healthcare resources.

Active
🇳🇱 Netherlands
Persuasive
MLA Diagnostics
Personalised measurement of melanoma malignancy

MLA Diagnostics improves melanoma diagnosis, offering personalized measurement of malignancy levels. Traditional diagnosis often leads to overtreatment or undertreatment, resulting in patient distress or undetected cancer progression. By analyzing methylation, our test provides accurate prognosis, enabling tailored treatment plans and saving lives. With the melanoma therapeutics market on the rise, our innovative solution is poised to make a significant impact, improve patient outcomes and create opportunities.

Active
🇳🇱 Netherlands
MLA Diagnostics
Aetherus
Pocket-size device for breathlessness

Aetherus tackles COPD, a debilitating lung disease, with their portable, non-invasive (pNIV) device. This device offers instant relief from breathlessness, improving patients' daily lives without adding to treatment regimens or causing side effects. By empowering patients to manage breathlessness anytime, anywhere, the pNIV device enhances COPD management and quality of life. This not only benefits patients but also alleviates the burden on healthcare systems, families, employers, and society at large.

Active
🇳🇱 Netherlands
Aetherus
PEP Health
Transforming healthcare quality management by real-time monitoring

PEP Health addresses the complexity of monitoring healthcare quality by offering a platform that tackles key challenges in quality assessment. By combining multiple sources of patient feedback, including social media, PEP provides near real-time assessments of quality for hospitals and departments. This approach reduces costs, improves timeliness, and enhances trustworthiness compared to traditional methods. With potential customers ranging from healthcare providers to patient organizations, PEP's underlying algorithm has been validated across industries, including higher education.

Active
🇬🇧 United Kingdom
PEP Health
MindAffect
Building the next generation of hearing & vision diagnostics

MindAffect is redefining what’s possible in diagnostics. By harnessing Brain-Computer Interface technology and AI, we can “read” how the brain reacts to sound and visual stimuli—objectively, in real time, and without requiring a single response from the patient. At the core is our patented and clinically validated Rapid CAEP® technology, which captures the brain’s automatic reactions. This breakthrough allows clinicians to diagnose patients who would otherwise be difficult or impossible to test—such as infants, seniors, and individuals with disabilities. In a world where over two billion people are underserved by current diagnostic methods, this changes everything. Our first product, Sofi, is the world’s fastest objective hearing diagnostic system, delivering accurate hearing thresholds in minutes. Sofi has been validated in leading hospitals, championed by key opinion leaders across the audiology community, and recognized globally—winning the Innovation Award at the World Congress of Audiology

Active
🇳🇱 Netherlands
MindAffect
Artifex
Off the shelf vascular graft alternative

ArtiFex tackles a solution for coronary and peripheral bypass surgeries. Traditional grafts from the great saphenous vein face issues like rapid degeneration, leading to complications. With millions of bypass surgeries conducted annually and a billion-dollar market for vascular grafts, there's a clear need for improvement. ArtiFex's innovative vascular graft, made of cobalt-chrome and cellulose promotes tissue regeneration, strength, and ensures blood flow without causing clotting or immune reactions.

Active
🇦🇹 Austria
Artifex

Our impact

15
Countries active in
€190M+
Raised by NLC ventures
20-25
Ventures built annually
2M+
Patients impacted
40+
Healthcare experts
70+
Active ventures in our portfolio

Explore our 2024 Impact report

Woman with hands in the air in nature
Maurits Schouten
00:00
/
00:00
I consider the medical sector to be very attractive. However, without the right expertise, network, and diversification, the risks can be significant. NLC removes these barriers and creates an attractive opportunity for me to participate as an investor in this sector.
Maurits Schouten

Maurits Schouten

Impact investor and Board Member of PYM

Peter Veldman
00:00
/
00:00
What I really like about NLC and what triggered my investment in the company is the strong culture and the quality of the team. NLC is able to de-risk the innovation cycle by building ventures at scale, thereby playing a leading role in shaping the future of healthcare.
Peter Veldman

Peter Veldman

Advisor and previous Deputy Head of Fund Operations at EQT Group

Invest in a portfolio of companies

A formal clothed man on a bridge in the city

Create a healthier future with us

Lars Olthof
Head of Venture Finance, Venture Investment Director